We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Solexa Introduces the Solexa Genome Analysis System
Product News

Solexa Introduces the Solexa Genome Analysis System

Solexa Introduces the Solexa Genome Analysis System
Product News

Solexa Introduces the Solexa Genome Analysis System


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Solexa Introduces the Solexa Genome Analysis System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Solexa, Inc. has announced the introduction of the Company’s DNA sequencing, expression profiling and micro-RNA analysis platform, the Solexa Genome Analysis System. 

The System, which is comprised of the Solexa 1G Genetic Analyzer, the Solexa Cluster Station and associated reagents, consumables, and software, is designed to generate over a billion bases of sequence per run. 

In addition to introducing the Solexa Genome Analysis System, the Company has announced plans to sequence the entire genome of a human in 2006 and to make sequence data publicly available.
 
Solexa claims that, with its significant data density and low operating cost, the Solexa Genome Analysis System has the potential to increase productivity while reducing costs by over two orders of magnitude relative to current DNA sequencing technologies.

The System is also intended to enable researchers to generate economical sequence-based digital readout of transcript abundance by assessing up to 5 million transcript tags per sample at costs comparable to those of hybridization arrays.
 
"This is an exceptionally exciting time for all of us at Solexa and the global research community," said John West, Solexa’s chief executive officer.

"We believe that the versatility and cost profile of our groundbreaking Solexa Genome Analysis System have the potential to improve productivity significantly at the largest sequencing and expression centers as well as at core facilities and even individual laboratories."

"This product introduction takes us a significant step closer to becoming the first company to deliver whole human genome sequencing at $100,000 per genome."
 
"We expect to begin accepting orders to purchase systems and to ship initial production units during the second quarter of next year," added Mr. West. 
 
Solexa also announced its intention to use the Solexa Genome Analysis System to sequence the entire genome of a human during 2006.

The individual DNA will be chosen by Solexa from among the set of anonymous samples recently used in the International Haplotype Mapping Project (HapMap) on the basis of scientific merit and the availability of fully informed consent for its use, including free public release of the sequence data.

This sequencing project is intended to afford the Company and researchers throughout the world the opportunity to compare results generated by the Solexa Genome Analysis System with other publicly available data.  
 
"In sequencing a human genome, our aim is to demonstrate the performance of the Solexa Genome Analysis System," stated Dr. David Bentley, chief scientist of Solexa.

"We expect this endeavor to display the suitability of our platform for rapid and cost-effective human genome sequencing and to pave the way for new applications in medical sequencing, such as the Cancer Genome Project."

"Solexa intends to release sequence data at regular intervals in 2006, so that researchers can objectively assess the output of the Solexa Genome Analysis System in comparison with previously validated, high-quality genetic data already in the public domain."

Advertisement